David S. Hong, MD

Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States

Presentation(s):

• Paper 20 - SUSTAINED DISEASE CONTROL WITH MDM2 INHIBITOR MILADEMETAN IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA

  Thursday, November 17, 2022
  1:24 PM – 1:32 PM